ロード中...
Ripretinib in gastrointestinal stromal tumor: the long-awaited step forward
Gastrointestinal stromal tumor (GIST) represents a paradigm for clinically effective targeted inhibition of oncogenic driver mutations in cancer. Five drugs are currently positioned as the standard of care for the treatment of advanced or metastatic GIST patients. This is the result of continuous, d...
保存先:
| 出版年: | Ther Adv Med Oncol |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
SAGE Publications
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7797597/ https://ncbi.nlm.nih.gov/pubmed/33473249 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835920986498 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|